2024
Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James L, Klaassen F, Sweeney S, Furin J, Franke M, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies N. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine 2024, 21: e1004401. PMID: 38701084, PMCID: PMC11101189, DOI: 10.1371/journal.pmed.1004401.Peer-Reviewed Original ResearchQuality-adjusted life yearsStandard of careDrug susceptibility testingRifampicin-resistant tuberculosisRR-TBEnd-of-treatmentLonger regimensTreatment strategiesTreatment outcomesBurden of drug-resistant TBCost-effective treatment strategyResistance to amikacinDrug-resistant TBSevere adverse eventsHistory of TBResistance to delamanidTB drug resistanceAnti-TB drugsLifetime costsAssociated treatment outcomesFQ-R.Average timeNatural history of TBFluoroquinolone resistanceFQ-R
2019
Predicting the Impact of Typhoid Conjugate Vaccines on Antimicrobial Resistance
Kaufhold S, Yaesoubi R, Pitzer VE. Predicting the Impact of Typhoid Conjugate Vaccines on Antimicrobial Resistance. Clinical Infectious Diseases 2019, 68: s96-s104. PMID: 30845324, PMCID: PMC6405272, DOI: 10.1093/cid/ciy1108.Peer-Reviewed Original ResearchConceptsChronic carriersAntimicrobial-resistant infectionsProportion of casesTyphoid-endemic settingsTyphoid infectionVaccination coverageResistant infectionsFuture vaccination campaignsOne-way sensitivity analysesTyphoid Conjugate VaccineTransmission dynamic modelSalmonella enterica serovar TyphiEmpiric prescribingConjugate vaccineEnterica serovar TyphiIntroduction of typhoidTreatment strategiesVaccination campaignTotal casesHealth outcomesNumber of casesRate of recoveryInfectionResistant strainsTotal number